

Phase IV Solutions & RWE, Labcorp Drug Development

First published: 21/07/2022

Last updated: 07/03/2024

Institution

Laboratory/Research/Testing facility

Non-Pharmaceutical company

Institution identification

Institution ID

48334

Institution countries



Germany



United Kingdom (Northern Ireland)

Type of institution

Laboratory/Research/Testing facility

Non-Pharmaceutical company

Institution website

<https://www.Labcorp.com>

ENCePP partner

Yes

Institution description

Labcorp Drug Development has more than 30 years of experience designing and executing Phase IV, pharmacovigilance, and real-world evidence (RWE) studies globally. We have deep expertise in epidemiology, study design, health economics and outcomes research, real-world data (RWD), safety, and patient-reported outcomes across all therapeutic areas in drugs and devices. We offer a full portfolio of services to provide innovative solutions for interventional studies, non-interventional studies, pragmatic trials, disease and drug registries, and database studies to examine efficacy/effectiveness and Other clinical outcomes, quality of life and Other patient-reported outcomes, safety, drug utilization, and healthcare resource use.

Institution details

Experience with collecting data directly from individual patients or respondents:

Yes

Interest in carrying out research that is funded by pharmaceutical companies:

Yes

Contact

To be provided To be provided TBC@TBC.com



TBC@TBC.com